Key Points
- CEO Daniel Faga sold 14,281 shares on Jan. 8 at an average price of $44.71 for proceeds of $638,503.51, leaving him with 479,344 shares (a 2.89% reduction in his ownership).
- Clustered insider selling is notable: the CEO sold additional blocks on Jan. 5 and 7 (totaling ~38,792 shares across those three trades, roughly $1.72M), and other executives have recently disposed of shares, which could create near‑term selling pressure despite large remaining insider holdings.
- Positive corporate catalysts include a $100 million share‑repurchase authorization (up to ~9.6% of shares), a UBS upgrade to “strong‑buy” with a $70 price target, and a partial motion to dismiss a royalty dispute that—if successful—could reduce future liabilities.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) insider Eric Loumeau sold 2,210 shares of the company's stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $98,809.10. Following the completion of the transaction, the insider owned 12,835 shares of the company's stock, valued at $573,852.85. The trade was a 14.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
AnaptysBio Price Performance
ANAB opened at $44.67 on Friday. The company has a market capitalization of $1.24 billion, a P/E ratio of -15.84 and a beta of 0.32. The firm's fifty day moving average price is $42.62 and its two-hundred day moving average price is $31.46. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $52.47.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.
AnaptysBio announced that its board has authorized a share repurchase plan on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued.
Analysts Set New Price Targets
ANAB has been the topic of several recent analyst reports. Guggenheim reaffirmed a "buy" rating on shares of AnaptysBio in a research note on Thursday, December 18th. Stifel Nicolaus cut their price objective on AnaptysBio from $80.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, December 11th. Weiss Ratings restated a "sell (d-)" rating on shares of AnaptysBio in a research note on Wednesday, October 8th. Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a "hold" rating in a report on Monday, November 10th. Finally, Wells Fargo & Company boosted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an "overweight" rating in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $60.40.
Get Our Latest Report on AnaptysBio
Institutional Investors Weigh In On AnaptysBio
A number of hedge funds have recently added to or reduced their stakes in ANAB. Larson Financial Group LLC increased its position in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 473 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC raised its position in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 1,377 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,326 shares in the last quarter. Finally, Covestor Ltd boosted its position in AnaptysBio by 131,540.0% in the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company's stock valued at $201,000 after buying an additional 6,577 shares during the last quarter.
AnaptysBio News Summary
Here are the key news stories impacting AnaptysBio this week:
- Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
- Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
- Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
- Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
- Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
- Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)
About AnaptysBio
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
